Navigation Links
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Date:1/16/2017

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2017 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on January 3, 2017 and January 16, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 214,000 shares of common stock to four new employees. These awards were granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel granted stock options to purchase shares of Rigel's common stock to (i) three of the employees with an exercise price of $2.38 per share, the closing price of Rigel's common stock on December 30, 2016, the first trading date prior to January 3, 2017, the effective date of such grants and (ii) one employee with an exercise price of $2.51 per share, the closing price of Rigel's common stock on January 13, 2017, the first trading date prior to January 16, 2017 the effective date of such grant. The stock options vest as follows: certain of the shares of common stock subject to the award vest in equal monthly installments over a two period subject to the achievement of one or more performance conditions and certain of the shares of common stock subject to the award vest in equal monthly installments over a four year period, with one-fourth of the shares subject to the award vesting on the first anniversary of the vesting commencement date.

Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor in a number of indications. The company completed and reported results from two Phase 3 clinical studies of fostamatinib in chronic immune thrombocytopenia (ITP) in August and October 2016. Rigel is also conducting a Phase 2 clinical trial with fostamatinib in autoimmune hemolytic anemia (AIHA) and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-300391187.html


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer
2. Rigel Announces Fourth Quarter and Year End 2015 Financial Results
3. Rigel to Present at Cowen and Company 36th Annual Health Care Conference
4. Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
5. Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)
6. Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Rigel Announces Third Quarter 2015 Financial Results
8. Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results
9. Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders
10. Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
11. Rigel Announces Second Quarter 2015 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... 11, 2019 , ... Bloodstream infections (BSI) leading to sepsis ... may not receive the most targeted therapy in time because traditional microbiological methods ... pathogens has shown improvement in patient outcomes, but not all molecular panels have ...
(Date:9/11/2019)... , ... September 11, 2019 , ... ... headquartered in Irving, Texas, that exclusively serves premier oral and maxillofacial surgeons – ... an oral and maxillofacial surgery practice with three locations in the Atlanta area. ...
(Date:9/11/2019)... ... 11, 2019 , ... With recent regulatory changes to state ... big pharma, nutraceutical manufacturers, food companies, and retailers. , Chronic CBD users represent ... to rise as access to hemp-derived CBD food products increases. In preclinical studies, ...
Breaking Medicine Technology:
(Date:9/17/2019)... , ... September 17, 2019 , ... Milwaukee-area dealership Hall Cars has hosted an annual ... by cancer. The event, entitled “Drive Out Cancer,” entails that for every vehicle purchased from ... Foundation. As the event lasts for 50 days, it has also been referred to as, ...
(Date:9/17/2019)... ... September 17, 2019 , ... National University has teamed ... Heart Association (AHA)-San Diego Chapter to raise awareness of heart health. Meb will ... September 21 in Balboa Park alongside National University System Chancellor and AHA Heart ...
(Date:9/17/2019)... ... September 17, 2019 , ... Encouraging a spirit of partnership ... Vice President of Insurance Plan Management for Dental Care Alliance, the 2019 Don ... at their annual conference, CONVERGE 2019, in Orlando. This award commends exemplary service ...
(Date:9/17/2019)... ... 17, 2019 , ... Since the registration of the NociScan ... in the US, Nocimed has been marketing its unique technology to healthcare clinicians ... MRI equipment to perform MR spectroscopy, NociScan detects the presence of chemical biomarkers ...
(Date:9/17/2019)... Ga. (PRWEB) , ... September 17, 2019 , ... ... social responsibility initiative contributing to the long-term health of canines – specifically golden ... of all Golden Retrievers will die from cancer – one out of five ...
Breaking Medicine News(10 mins):